Literature DB >> 10792078

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer.

H Miyamoto1, Y Kubota, S Noguchi, K Takase, J Matsuzaki, M Moriyama, S Takebayashi, H Kitamura, M Hosaka.   

Abstract

OBJECTIVES: To evaluate c-erbB-2 gene amplification and its prognostic significance in transitional cell carcinoma of the bladder.
METHODS: Alterations in the gene copy number of c-erbB-2 were detected in 57 bladder tumor samples using a method based on the polymerase chain reaction.
RESULTS: Eighteen tumors (32%) showed gene amplification of c-erbB-2, which correlated with tumor grade and stage. A strong association of c-erbB-2 amplification with patient survival was also found. The amplification resulted in a significantly poorer prognosis among the patients with high-grade and/or invasive tumors. Multivariate analysis revealed that c-erbB-2 amplification and tumor grade were independent prognostic factors.
CONCLUSIONS: Our data indicate a possible role of the c-erbB-2 gene in the development of aggressive behavior in bladder tumors. Moreover, the use of c-erbB-2 gene amplification, together with tumor grade and stage, could provide an accurate basis for determining the prognosis of bladder cancer.

Entities:  

Mesh:

Year:  2000        PMID: 10792078     DOI: 10.1016/s0090-4295(99)00604-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  21 in total

1.  The expression of keratin 6 is regulated by the activation of the ERK1/2 pathway in arsenite transformed human urothelial cells.

Authors:  Andrea Slusser-Nore; Scott H Garrett; Xu Dong Zhou; Donald A Sens; Mary Ann Sens; Seema Somji
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-10       Impact factor: 4.219

Review 2.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

3.  Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters.

Authors:  M Gallucci; F Guadagni; R Marzano; C Leonardo; R Merola; S Sentinelli; E M Ruggeri; R Cantiani; I Sperduti; F de la Iglesia Lopez; A M Cianciulli
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

Review 4.  Adjuvant chemotherapy for transitional cell carcinoma of the bladder: paradigms for the design of clinical trials.

Authors:  Michelle Boyar; Daniel P Petrylak
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

5.  HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.

Authors:  Yuka Sasaki; Takeshi Sasaki; Taketo Kawai; Teppei Morikawa; Keisuke Matsusaka; Akiko Kunita; Haruki Kume; Ichiro Aoki; Yukio Homma; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

6.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

Authors:  M Laé; J Couturier; S Oudard; F Radvanyi; P Beuzeboc; A Vieillefond
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

7.  Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.

Authors:  Surendra B Kolla; Amlesh Seth; Manoj K Singh; Narmada P Gupta; Ashok K Hemal; Prem N Dogra; Rajeev Kumar
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 8.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

9.  Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.

Authors:  Wassim Kassouf; Peter C Black; Tomasz Tuziak; Jolanta Bondaruk; Sangkyou Lee; Gordon A Brown; Liana Adam; Caimiao Wei; Keith Baggerly; Menashe Bar-Eli; David McConkey; Bogdan Czerniak; Colin P Dinney
Journal:  J Urol       Date:  2007-11-19       Impact factor: 7.450

10.  Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

Authors:  Matthew D Galsky; Tal Zaks; Habib Hassani; Linda Vocila; Guru Sonpavde; Thomas E Hutson; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2009-03-06       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.